Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Eric Ostertag

Poseida Therapeutics, Inc.

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.

Metric
Company Name	Poseida Therapeutics, Inc.	BridgeBio Pharma	Ginkgo Bioworks Holdings, Inc.
Symbol	PSTX		DNA
MSH ID	COM:POSEIDA	COM:BRIDGEBIOPHARMA	COM:GINKGOBIOWORKS
Market	STOCKS	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage	Post-IPO Equity	Post-IPO Equity	Grant
Employee Count	335		1.22K
Website	poseida.com	bridgebiopharma.com	ginkgobioworks.com
LinkedIn	poseida-therapeutics-inc-		ginkgo-bioworks
Founders

Metric
Market Cap	288.93M		725.64M
Enterprise Value
Monthly Web Traffic	2.82K	23.81K	20.69K
Web Traffic Growth	1.38	0.19	-0.17
Valuation
Raised Capital	50M	250M

Metric
Revenue	64.70M	251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	64.70M	142.64M
EBITDA	-129.50M	-600.68M
Operating Income	-129.50M	-672.23M
Net Income	-123.43M	-892.87M
EPS	-0.00	-0.46
Diluted EPS	-0.00	-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.92	0.75
Operating Profit Margin	-1.34	-3.34
EBITDA Margin	-2.00	-2.39
Net Profit Margin	-1.26	-3.55
Return on Equity	-0.95	-0.65
Return on Assets	-0.37	-0.54
Return on Capital Employed	-0.60	-0.51

COM:POSEIDA

Poseida Therapeutics, Inc.

Last Close

2.71

22/11 21:00

Market Cap

288.93M

Beta: -

Volume Today

364.94K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.45	-2.78
P/B Ratio	2.63	1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.75	93.70
EV Multiple	-1.36	-1.34

Metric
Days Sales Outstanding	63.78	73.17
Days Payables Outstanding		50.57
Days Inventory Outstanding		0.27
Operating Cycle	53.21	46.33
Cash Conversion Cycle	-64.17	-7.39
Asset Turnover	0.31	0.15

Metric
Operating Cash Flow	-92.17M	-295.50M
Free Cash Flow	-95.23M	-336.30M
Cash Flow to Debt	0.04	-0.63
Operating Cash Flow/Sales	0.03	-1.14
Free Cash Flow Yield	-0.19	-0.16

Metric
Cash & Equivalents	44.47M	948.86M
Accounts Receivable	77K	50.07M
Inventory		46K
Goodwill	4.23M	49.24M
Debt to Capitalization	0.58	0.35
Debt to Assets	0.29	0.20
Current Ratio	3.28	6.78
Quick Ratio	3.10	5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.46	0.94
R&D to Revenue	2.99	2.05
SG&A to Revenue	0.76	1.32